HC Wainwright Lowers Earnings Estimates for Atossa Genetics

Atossa Genetics Inc. (NASDAQ:ATOS) – Stock analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of Atossa Genetics in a report released on Thursday, March 26th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.34) per share for the quarter, down from their previous forecast of ($1.20). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.03) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at ($0.20) EPS.

A number of other research firms have also commented on ATOS. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets raised their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Atossa Genetics currently has a consensus rating of “Hold” and a consensus price target of $68.33.

Atossa Genetics Stock Performance

ATOS opened at $4.72 on Monday. The firm has a market cap of $40.64 million, a P/E ratio of -1.31 and a beta of 1.42. The business has a 50 day moving average price of $5.71 and a 200 day moving average price of $9.90. Atossa Genetics has a twelve month low of $3.76 and a twelve month high of $19.35.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its stake in shares of Atossa Genetics by 39.9% in the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares during the last quarter. Bank of America Corp DE raised its stake in Atossa Genetics by 55.8% during the 3rd quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after purchasing an additional 55,568 shares during the last quarter. Graham Capital Management L.P. raised its stake in Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after purchasing an additional 45,923 shares during the last quarter. XTX Topco Ltd boosted its holdings in Atossa Genetics by 581.2% in the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after purchasing an additional 144,412 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the period. 12.74% of the stock is owned by institutional investors.

Atossa Genetics News Roundup

Here are the key news stories impacting Atossa Genetics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $25 price target, giving investors a clear upside thesis that can support the stock. Article Title
• Positive Sentiment: The analyst substantially improved long‑range loss estimates (FY2027–FY2029 and into FY2030), trimming multi‑year projected losses and signaling a path toward much smaller deficits in later years — a development that can boost investor sentiment around potential recovery/value. Article Title
• Positive Sentiment: HC Wainwright raised several quarter estimates (notably Q3 and Q4 2026 and overall FY2026 modestly improved versus their prior view), which trims some near‑term downside in forecasts and supports a less bearish intermediate outlook.
• Neutral Sentiment: Consensus remains negative on GAAP EPS over the next few years and the company is still early in its development stage — the analyst changes reduce but do not eliminate structural risk; this is a high‑volatility, binary biotech exposure.
• Negative Sentiment: HC Wainwright increased near‑term quarterly loss estimates for Q1 and Q2 2026 (worse EPS for those quarters), and FY2026 still projects a sizable loss (~($4.75) per share), underscoring short‑term cash burn and execution risk that could pressure the stock if clinical or financing milestones slip.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.